Pipeline

Man looking at computer screen

Deucrictibant is the only oral B2-receptor antagonist currently in clinical development.

Pharvaris has a platform of novel, potent and selective B2-receptor antagonist small molecules for the treatment of bradykinin-mediated diseases. Pharvaris’ pipeline consists of investigational therapies that are designed to treat hereditary angioedema (HAE).

Molecule
Indication
Formulation
Discovery
Preclinical
Phase 1
Phase 2
Phase 3

Deucrictibant*

HAE

Solution

HAE

On-demand

PHVS416

(immediate-release capsule)

HAE

Prophylaxis

PHVS719

(extended-release tablet)
proof of concept  

PHAXX

Undisclosed

*The FDA has placed a hold on clinical trials of deucrictibant for long-term prophylaxis in the U.S.; see our recent press releases and corporate presentation for an update on our clinical programs

Treatment Strategy

During the shared decision process, people living with HAE and their treating physicians, may opt for treatment of attacks (on-demand treatment) or may prefer to prevent attacks (prophylactic treatment) based on clinical assessment and personal choice.

By brining the promise of both these new treatment options to people living with HAE, Pharvaris aims to enable those with HAE to have fewer disruptions in their daily activities, resulting in an improved quality of life.

Product Summary

PHVS416 - Immediate Release
Deucrictibant Immediate-Release Capsule

  • Rapid exposure
  • Effective symptom mitigation

Rapidly reaches therapeutic exposure within 30 minutes, making it optimally formulated to treat on-demand attacks. Its rapid onset,* one dose symptom resolution, and oral delivery fulfills an unmet need of people living with HAE.

PHVS719 - Extended Release
Deucrictibant Extended-Release Tablet

  • Sustained attack suppression

Maintains sustained therapeutic exposure for over 24 hours, allowing for once-daily administration to prevent HAE attacks. It is designed to reduce HAE attack frequency by 80-90% over 24 weeks.**

**Aspirational, to be confirmed with clinical data

Disease Focus

Deucrictibant

Deucrictibant is the only oral B2-receptor antagonist currently in clinical development. Our aim is to develop distinct, optimized formulations for both acute treatment, through rapid onset of activity, and preventive treatment, through prolonged efficacy, of HAE.

*The FDA has placed a hold on the clinical trials of deucrictibant for long-term prophylaxis in the U.S.

Explore our latest Publications, Posters and Presentations